High cholesterol levels may impair fertility in couples trying to achieve a pregnancy, according to a study by researchers at the National Institutes of Health, the University at Buffalo (New York), and Emory University in ...
May 20, 2014
0
0
Among patients with persistently high cholesterol despite high-intensity statin therapy, the proprotein convertase subtilisin-kexin 9 (PCSK9) inhibitor alirocumab reduced rates of major adverse cardiovascular events (MACE) ...
Mar 12, 2018
0
5
The first major clinical trial to include a blinded, placebo-controlled "statin re-challenge" in patients with a history of muscle-related side effects sheds new light on statin-associated muscle symptoms, according to research ...
Apr 4, 2016
0
4
Some individuals remain at high risk for developing cardiovascular disease even after preventative treatment with cholesterol-lowering medications. This persistent risk has been linked to triglyceride levels, which can remain ...
Jul 11, 2016
0
2
Evolocumab (trade name: Repatha) has been approved since July 2015 for two therapeutic indications: on the one hand, for hypercholesterolaemia or mixed dyslipidaemia, and on the other, for homozygous familial hypercholesterolaemia. ...
Dec 22, 2015
0
0
A common mutation in the TM6SF2 gene raises liver values but at the same time improves blood lipid values in healthy children, according to a recent study from the University of Eastern Finland. Children who carry the gene ...
Jan 13, 2016
0
4
Evolocumab, one of the new targeted PCSK9 inhibitor drugs that has been shown to dramatically lower levels of low-density lipoprotein (LDL), or "bad" cholesterol, also significantly lowers the risk of cardiovascular events ...
Mar 17, 2017
0
0
(HealthDay)—In patients with type 2 diabetes being treated with a dipeptidyl peptidase-4 inhibitor (DPP4-I), use of anagliptin (ANA) may improve low-density lipoprotein cholesterol (LDL-C) levels, with the effect mediated, ...
Sep 19, 2017
0
1
In a clinical program that was terminated early, the experimental PCSK9 inhibitor bococizumab, when given on top of effective statin therapy, had widely varying effects on LDL cholesterol levels and had no benefit on cardiovascular ...
Mar 17, 2017
0
1
Numerous studies have suggested a relationship between cardiovascular disease risk factors and prostate cancer. A new study by researchers at the University of California, San Diego School of Medicine, with colleagues in ...
Apr 30, 2014
0
0
